EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)

Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis

Michelle N Rheault iD, Charles E Alpers, Jonathan Barratt iD, Stewart Bieler, Pietro Canetta iD, Dong-Wan Chae, Gaia Coppock, Ulysses Diva, Loreto Gesualdo, Hiddo J L Heerspink, Jula K Inrig, Gianna M Kirsztajn und 16 weitere

New England Journal of Medicine · 28.12.2023 · 389 (26) · 2436-2445

DOI: 10.1056/nejmoa2308550 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 28.12.2023. Verfasst von Michelle N Rheault und 27 weiteren Autor:innen. Beteiligte Einrichtung: From the Division of Pediatric Nephrology, University of Minnesota Medical School, Minneapolis (M.N.R.); the Department of Laboratory Medicine and Pa…. Hauptthemen laut MEDLINE: Glomerulosclerosis, Focal Segmental, Irbesartan, Proteinuria. Die Arbeit wurde bisher 124-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: NIDDK NIH HHS, Travere Therapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glomerulosclerosis, Focal SegmentalIrbesartanProteinuriaHumansBiomarkersCreatinineGlomerular Filtration RateChildAdolescentYoung AdultAdultMiddle AgedAgedRemission InductionSpiro CompoundsSulfonamides

Substanzen

BiomarkersCreatinineIrbesartansparsentanSpiro CompoundsSulfonamides

Autor:innen und Institutionen

  • From the Division of Pediatric Nephrology, University of Minnesota Medical School, Minneapolis (M.N.R.); the Department of Laboratory Medicine and Pathology, University of Washington, Seattle (C.E.A.); the Department of…

ORCID-Profile: Michelle N Rheault, Jonathan Barratt, Pietro Canetta

Förderung

  • NIDDK NIH HHS
  • Travere Therapeutics

Zitieren

APA

Rheault, M. N., Alpers, C. E., Barratt, J., Bieler, S., Canetta, P., Chae, D. W., Coppock, G., Diva, U., Gesualdo, L., Heerspink, H. J. L., Inrig, J. K., Kirsztajn, G. M., Kohan, D., Komers, R., Kooienga, L. A., Lieberman, K., Mercer, A., Noronha, I. L., Perkovic, V., …, & DUPRO Steering Committee and DUPLEX Investigators (2023). Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis. New England Journal of Medicine, 389(26), 2436-2445. https://doi.org/10.1056/nejmoa2308550

Vancouver

Rheault MN, Alpers CE, Barratt J, Bieler S, Canetta P, Chae DW, et al. Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis. New England Journal of Medicine. 2023;389(26):2436-2445. doi:10.1056/nejmoa2308550

BibTeX
@article{Rheault2023,
  author = {Rheault, Michelle N and Alpers, Charles E and Barratt, Jonathan and Bieler, Stewart and Canetta, Pietro and Chae, Dong-Wan and Coppock, Gaia and Diva, Ulysses and Gesualdo, Loreto and Heerspink, Hiddo J L and Inrig, Jula K and Kirsztajn, Gianna M and Kohan, Donald and Komers, Radko and Kooienga, Laura A and Lieberman, Kenneth and Mercer, Alex and Noronha, Irene L and Perkovic, Vlado and Radhakrishnan, Jai and Rote, William and Rovin, Brad and Tesar, Vladimir and Trimarchi, Hernán and Tumlin, James and Wong, Muh Geot and Trachtman, Howard and DUPRO Steering Committee and DUPLEX Investigators, DUPRO Steering Committee and DUPLEX Investigators},
  title = {Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis},
  journal = {New England Journal of Medicine},
  year = {2023},
  volume = {389},
  number = {26},
  pages = {2436--2445},
  doi = {10.1056/nejmoa2308550}
}
Kostenlos starten →